Lineage Cell Therapeutics (LCTX) Income Statement: Revenue & Earnings

Lineage Cell Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Lineage Cell Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	9.50	8.95	14.70	4.34	0.77	3.52	1.42
Cost of Revenue	0.33	0.67	0.73	1.43	0.39	-0.41	0.30
Gross Profit	9.17	8.27	13.98	2.92	0.39	3.10	1.11
Operating Expenses
Research & Development	12.47	15.71	13.99	33.91	12.32	17.95	20.96
Selling, General & Administrative	18.17	17.30	22.51	18.21	15.57	24.03	24.73
Operating Expenses	30.64	33.01	36.50	52.13	27.89	-41.98	42.11
Operating Income	-21.48	-24.73	-22.52	-49.21	-26.45	-42.39	-41.00
Other Income/Expense
Interest Income	1.72	1.63	0.83	0.00	1.04	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	1.18	-0.18	-4.12	0.21	-3.48	-11.70	-6.85
Income
Income Before Tax	-18.58	-23.28	-25.81	-43.27	-21.92	-19.23	-47.13
Income Tax Expense	0.00	-1.80	0.54	0.00	-1.24	-7.41	-0.35
Net Income	-18.61	-21.49	-26.27	-43.02	-20.65	-11.71	-45.99
Net Income - Continuous Operations	-18.58	-21.48	-26.35	-43.27	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-20.87	-24.04	-21.79	-48.34	-24.41	-16.11	-37.72
EBIT	-21.48	-24.73	-22.52	-49.21	-26.45	-19.23	-41.00
Depreciation & Amortization	0.61	0.69	0.58	0.87	0.82	-1.10	0.00
Earnings Per Share
Basic EPS	-	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-	-
Basic Shares Outstanding	200.19	172.66	169.79	164.50	0.15	0.15	126.90
Diluted Shares Outstanding	200.19	172.66	169.79	164.50	0.15	522.68	126.90